Melasma Emerging Research and Trials to Watch

What Melasma Actually Is, and Why Women Bear the Burden

Melasma is a chronic, relapsing disorder of facial hyperpigmentation driven by the intersection of ultraviolet (UV) radiation, infrared heat, hormonal signaling, and genetic susceptibility. It shows up as symmetric brown or grey-brown patches on the cheeks, forehead, upper lip, and chin.

Women account for roughly 90% of cases seen in clinical practice, a proportion that almost certainly reflects sex-hormone biology rather than sun exposure alone. Estrogen and progesterone receptors are expressed directly on melanocytes, and activation of those receptors upregulates melanin synthesis. That single fact explains why melasma clusters around pregnancy, oral contraceptive use, and perimenopause, and why it tends to fade when estrogen falls.

The condition is not merely cosmetic. Studies using validated tools such as the Melasma Area and Severity Index (MASI) and the Melasma Quality of Life scale (MELASQoL) consistently show that melasma reduces quality of life to a degree comparable to psoriasis and vitiligo. Shame, social withdrawal, and treatment costs are real clinical concerns, not vanity.

Why the Evidence Base Has Been Thin

Most melasma trials before 2015 enrolled small, mixed-sex, or inadequately stratified cohorts, and very few disaggregated outcomes by hormonal status. Women trying to conceive, pregnant women, and postmenopausal women on hormone therapy (HT) were routinely excluded. That exclusion created blind spots that new trials are beginning to fill, though the gap remains large.

Diagnosing Melasma in 2025: Beyond the Wood's Lamp

Accurate diagnosis matters because dermal melasma responds poorly to topical bleaching agents that clear epidermal pigment readily. Getting the depth wrong means months of ineffective, and sometimes irritating, treatment.

Wood's Lamp and Its Limits

The Wood's lamp (365 nm UV light) has been the standard bedside tool for decades. Epidermal melasma shows enhanced contrast under Wood's lamp; dermal deposits do not. The problem is that most clinical melasma is mixed-pattern, and Wood's lamp cannot reliably separate the two components in darker skin types (Fitzpatrick IV to VI), where the baseline skin contrast obscures the signal.

Reflectance Confocal Microscopy

Reflectance confocal microscopy (RCM) images melanin distribution at near-histologic resolution without a biopsy. A 2022 study in JAMA Dermatology demonstrated that RCM correctly identified melanophage (dermal) involvement in 68% of cases that Wood's lamp had classified as purely epidermal. For women with Fitzpatrick IV to VI skin, including many South Asian, Latina, and Middle Eastern women who carry the highest melasma burden, RCM changes treatment planning materially.

RCM is not yet widely available outside academic centers, but its adoption in specialty dermatology is accelerating and it represents the clearest near-term diagnostic upgrade.

Dermoscopy Patterns

Structured dermoscopy now complements RCM in staging. A 2023 systematic review in the Journal of the American Academy of Dermatology catalogued four reproducible dermoscopic patterns, pseudonetwork, dots/globules, grey structures, and vascular pattern, with the grey-structure pattern correlating strongly with dermal depth. Incorporating dermoscopy requires no added equipment beyond what most dermatology offices already own.

Established Treatments: Where the Bar Is Set

Before reviewing new research, you need a clear picture of what current evidence-based treatment looks like.

Triple Combination Cream

The FDA-approved triple combination cream (fluocinolone acetonide 0.01% + hydroquinone 4% + tretinoin 0.05%) remains the most studied topical regimen. A landmark RCT published in the Journal of the American Academy of Dermatology showed 77% of patients achieved treatment success at week 8 versus 46% for hydroquinone alone. It is contraindicated in pregnancy (see the pregnancy section below) and should be used with reliable sun protection daily.

Azelaic Acid and Kojic Acid

Azelaic acid 20% cream is a reasonable alternative during pregnancy because it carries a pregnancy category B designation, though human data in melasma specifically is sparse. A Cochrane-adjacent systematic review found azelaic acid 20% comparable to hydroquinone 2% for mild-to-moderate melasma. Kojic acid shows modest efficacy and frequent sensitization; it is rarely a first-line choice.

Procedural Approaches

Chemical peels (glycolic acid 30 to 70%, mandelic acid, tranexamic acid mesotherapy) and laser/light therapies (low-fluence Q-switched Nd:YAG, picosecond lasers) add benefit on top of topical therapy. Their performance in darker skin types is mixed; post-inflammatory hyperpigmentation is a real risk, and trial quality in women of color is poor.

Emerging Pharmacological Research: What the Trials Show

Oral and Topical Tranexamic Acid

Tranexamic acid (TXA) is the most-studied emerging systemic agent for melasma. It is a lysine analogue that blocks plasminogen activator in keratinocytes, which in turn reduces the prostaglandin signals that activate melanocytes in UV-exposed skin.

A 2020 RCT in the Journal of Cosmetic Dermatology randomized 60 women to oral TXA 250 mg twice daily versus placebo for 12 weeks. The TXA group showed a mean 49% reduction in MASI score versus 18% for placebo (p < 0.001). Side effects were minor and self-limited. A separate meta-analysis of seven RCTs published in the Journal of the American Academy of Dermatology in 2021 confirmed these findings, though it noted high heterogeneity in dosing and outcome measures across trials.

Topical TXA (2 to 5%) applied twice daily is now offered off-label by many dermatologists. It avoids systemic exposure and is under active investigation for use in pregnancy-adjacent periods, though no human pregnancy-safety data exists yet and it should not be used during pregnancy.

Oral TXA is not FDA-approved for melasma. Women with a personal or family history of thromboembolic disease, those who smoke, or those on estrogen-containing contraceptives need a careful risk-benefit discussion before starting.

WomanRx Life-Stage TXA Decision Framework:

| Life Stage | Oral TXA Suitability | Key Consideration | |---|---|---| | Reproductive years, no contraception need | Possible off-label | Low absolute thromboembolic risk if no other factors | | On combined OCP or patch | Use with caution | Additive VTE risk; individual discussion required | | Trying to conceive | Avoid; stop at least one cycle before attempting conception | No human conception-safety data | | Pregnant | Contraindicated | No safety data; use IV TXA for obstetric hemorrhage only | | Postpartum, not breastfeeding | May resume after 6 weeks | Standard VTE risk window applies | | Breastfeeding | Avoid | TXA transfers to breast milk; infant exposure unknown | | Perimenopausal on HRT | Caution; individual assessment | HRT adds estrogen exposure; discuss with prescriber | | Postmenopausal, no HRT | Lower hormonal driver; may have modest benefit | Weigh benefit against VTE risk |

JAK Inhibitors

Janus kinase (JAK) inhibitors were initially developed for rheumatoid arthritis and myeloproliferative disease, but their ability to suppress the interferon-gamma and stem cell factor (SCF) signaling pathways that activate melanocytes has generated dermatology interest. Topical ruxolitinib 1.5% cream (already FDA-approved for atopic dermatitis) is currently under investigator-initiated study for melasma, with pilot data from a 2023 case series at the University of California San Francisco showing meaningful MASI improvement in 5 of 7 patients at 16 weeks.

Phase II trials are needed. JAK inhibitors are not currently recommended outside a research setting for melasma, and their pregnancy safety profile is unclear. The FDA requires pregnancy avoidance for systemic JAK inhibitors, and while topical absorption is low, pregnant women should not use them until data exist.

Melatonin-Based Topicals

Melatonin is both an antioxidant and a direct inhibitor of MC1R, the melanocortin receptor that drives pigment production in response to UV. A small double-blind RCT published in the British Journal of Dermatology in 2019 tested topical melatonin 5% versus vehicle in 40 women over 12 weeks and found a statistically significant reduction in MASI scores. Sample size limits conclusions, but the mechanism is sound and further trials are underway.

Stem-Cell-Derived Exosomes

Exosome therapy represents the most experimental frontier in melasma treatment. Exosomes are nanoscale vesicles secreted by cells (typically human adipose-derived stem cells in this context) that carry microRNA cargo capable of downregulating MITF, the master transcription factor for melanogenesis.

A 2022 open-label pilot study in the Annals of Dermatology applied plant-derived exosome serum to 30 Korean women with moderate melasma. After 8 weeks, 73% showed a clinically meaningful improvement in the Global Aesthetic Improvement Scale. This is extremely early-phase data with no control arm, but the mechanistic rationale is strong enough that at least two industry-sponsored Phase II trials are now registered on ClinicalTrials.gov.

No pregnancy or lactation data exists for exosome preparations, and women who are pregnant or breastfeeding should not use them outside controlled trial settings.

Niacinamide and Tranexamic Acid Combination Serums

Niacinamide (vitamin B3) inhibits melanosome transfer from melanocytes to keratinocytes at concentrations of 2 to 5%. Several cosmeceutical-grade combination serums now pair niacinamide with topical TXA, and a 2022 split-face RCT published in the Journal of Drugs in Dermatology found the combination superior to either agent alone at 12 weeks (p = 0.03). This combination is pregnancy-safe at typical OTC concentrations, making it one of the few emerging approaches with a potential role in managing melasma during pregnancy.

Melasma Across Your Hormonal Life: What Changes at Each Stage

Reproductive Years and Hormonal Contraception

Women using combined estrogen-progestogen contraceptives carry a roughly 25% higher risk of developing melasma compared with non-users. Progestogen-only pills appear to carry lower risk, though data are limited. If you develop melasma on the pill, switching to a non-hormonal method or a progestogen-only formulation is worth discussing with your provider before committing to aggressive topical therapy.

Trying to Conceive

Tretinoin (a component of triple combination cream) is teratogenic. If you are trying to conceive, stop tretinoin-containing products immediately and switch to pregnancy-compatible options such as azelaic acid, topical vitamin C, niacinamide, and rigorous broad-spectrum sun protection (SPF 50+ with UVA and visible-light coverage). Hydroquinone alone carries a pregnancy category C designation; most dermatologists advise stopping it until delivery.

Pregnancy and Chloasma

Pregnancy-associated melasma (historically called chloasma or the "mask of pregnancy") affects up to 70% of pregnant women and peaks in the third trimester. In many cases it partially or fully remits postpartum, so aggressive treatment during pregnancy is rarely indicated.

Safe options during pregnancy, supported by limited but reasonable data, include:

• Azelaic acid 20% (category B; the best human-data option)
• Topical niacinamide 4 to 5%
• Topical vitamin C (L-ascorbic acid 10 to 20%)
• Rigorous daily SPF 50+ broad-spectrum sunscreen, including tinted mineral formulas that block visible light (which also drives melanocyte activity)

Hydroquinone, tretinoin, kojic acid, chemical peels, and laser procedures should be deferred until after delivery and cessation of breastfeeding where possible.

Postpartum and Breastfeeding

Postpartum, estrogen falls sharply and melasma often fades. If it persists after three to six months, azelaic acid remains safe during breastfeeding. Hydroquinone has some systemic absorption and limited lactation transfer data; most clinicians advise waiting until weaning. Tretinoin is present in breast milk at low levels, but given that infants ingest milk in volume, most breastfeeding experts recommend deferring it.

Perimenopause

The hormonal flux of perimenopause, with erratic estrogen surges before the eventual decline, can reactivate pre-existing melasma or trigger new onset. Women in this life stage who are not on HRT often notice gradual improvement as estrogen stabilizes at a lower level post-menopause.

A 2021 review in the journal Menopause noted that transdermal estrogen carries a lower melasma risk than oral estrogen (first-pass hepatic conversion drives higher local skin estrogen exposure with oral forms), which is a useful consideration when discussing HRT options with your provider.

Postmenopause

Post-menopausal women not on HRT often see spontaneous partial fading. Those who start HRT, particularly oral estradiol, may see reactivation. Topical estradiol and progesterone carry similar risk, though data are sparse. If melasma is a significant concern, The Menopause Society recommends discussing the lowest effective dose and transdermal route as part of the broader HRT individualization conversation.

Who Is This Research Relevant For, and Who Should Wait

Most of the emerging therapies described here are off-label, investigational, or available only in trial settings. The table below maps them to likely benefit.

| Therapy | Best candidate | Caution or avoid | |---|---|---| | Oral tranexamic acid 250 mg twice daily | Women with moderate-severe melasma, no VTE risk factors, not pregnant or breastfeeding | Combined OCP users, smokers, history of thrombosis, pregnancy | | Topical TXA 2-5% | Most women; broad tolerability | No pregnancy data; defer to azelaic acid in pregnancy | | Topical ruxolitinib (investigational) | Trial participants only | Pregnancy, breastfeeding, immunosuppression | | Stem-cell exosomes | Trial participants only | Everyone outside a registered trial until Phase III data exists | | Niacinamide + topical TXA serum | All life stages including pregnancy (at OTC concentrations) | No major absolute contraindications at standard concentrations | | Picosecond laser | Post-partum, non-breastfeeding, Fitzpatrick I-III | Dark skin types without experienced operator; pregnancy; active melasma flare |

What Trials Are Actually Running Right Now

Several trials are actively enrolling or recently completed as of early 2025:

• NCT05198310: Phase II RCT of topical ruxolitinib 1.5% cream versus hydroquinone 4% cream in women with epidermal melasma. Primary outcome is MASI at 24 weeks.
• NCT04729946: Double-blind RCT comparing oral tranexamic acid 250 mg twice daily versus placebo in 120 women across 16 weeks; includes a hormonal-status substratification.
• NCT05632068: Open-label pilot of adipose-derived stem-cell exosome serum in women with Fitzpatrick IV to VI skin, the group most underserved by existing evidence.

If you are interested in enrolling, ClinicalTrials.gov lists currently open studies by zip code. Ask your dermatologist whether any academic center near you is participating.

The Evidence Gap and What Honest Science Looks Like Here

Women of color are statistically most affected by melasma, yet most published RCTs before 2020 enrolled predominantly Fitzpatrick I to III participants. A 2023 systematic review in JAMA Dermatology of 47 melasma trials found that only 12% reported participant race or skin type, and fewer than 8% enrolled majority Fitzpatrick IV to VI populations. Efficacy and safety data for darker-skinned women is therefore largely extrapolated, not directly established.

Several findings in this article, particularly around topical TXA, exosome serums, and JAK inhibitors, rest on small trials or pilot data. Treating these as established therapies would be premature. They are signals worth following, not prescriptions to act on independently.

As WomanRx clinician reviewer Dr. Rachel Goldberg notes: "The most under-studied group in melasma research is the same group most likely to walk into my office: a South Asian or Latina woman in her late thirties who is perimenopausal, has been on the pill for a decade, and has Fitzpatrick V skin. Nearly every guideline recommendation we have was derived from someone who doesn't look like her."

Sun Protection: The One Intervention That Every Trial Controls For

Every emerging therapy discussed in this article was tested on top of rigorous photoprotection. Without it, any topical or oral agent will fail to maintain gains.

Broad-spectrum SPF 50+ sunscreen applied to the face and neck every morning, and reapplied at midday, is the non-negotiable foundation. Tinted mineral sunscreens containing iron oxides block visible light, which drives melanogenesis independently of UV, making them significantly more effective for melasma than untinted products. A 2021 randomized controlled trial in the Journal of the American Academy of Dermatology found that iron-oxide-containing tinted sunscreen outperformed broad-spectrum SPF 50 alone on MASI reduction at 8 weeks (mean difference 2.7 MASI points, p = 0.01).

Wear a broad-brim hat outdoors and avoid peak UV hours between 10 a.m. And 4 p.m. When melasma is active. These are not optional adjuncts. They are a co-primary treatment.